|
US8809273B2
(en)
*
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
MX380504B
(es)
|
2010-06-03 |
2025-03-12 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
AU2012255860C1
(en)
|
2011-05-17 |
2015-12-10 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
KR20140048968A
(ko)
|
2011-07-13 |
2014-04-24 |
파마시클릭스, 인코포레이티드 |
브루톤형 티로신 키나제의 억제제
|
|
CN103889987B
(zh)
*
|
2011-07-19 |
2016-09-14 |
默沙东有限责任公司 |
作为btk抑制剂的选择的咪唑并吡嗪类
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
HK1206073A1
(en)
|
2012-07-24 |
2015-12-31 |
药品循环有限责任公司 |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
CA2886240A1
(en)
*
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
JP6313772B2
(ja)
*
|
2012-10-04 |
2018-04-18 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
US9481682B2
(en)
|
2013-01-23 |
2016-11-01 |
Merck Sharp & Dohme Corp. |
Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
KR20160013204A
(ko)
*
|
2013-05-30 |
2016-02-03 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
|
|
JP6612751B2
(ja)
|
2013-07-31 |
2019-11-27 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
|
|
WO2015057992A1
(en)
*
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
EP3076974A1
(en)
|
2013-12-05 |
2016-10-12 |
Acerta Pharma B.V. |
Therapeutic combination of a pi3k inhibitor and a btk inhibitor
|
|
US9834554B2
(en)
|
2013-12-20 |
2017-12-05 |
Merck Sharp & Dohme Corp. |
BTK inhibitors
|
|
US9637486B2
(en)
|
2013-12-20 |
2017-05-02 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
|
WO2015110923A2
(en)
*
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
WO2015185998A2
(en)
|
2014-04-11 |
2015-12-10 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
|
|
WO2015193740A2
(en)
*
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
|
CA2959602A1
(en)
*
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
WO2016020901A1
(en)
|
2014-08-07 |
2016-02-11 |
Acerta Pharma B.V. |
Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
|
|
US20170231995A1
(en)
*
|
2014-08-11 |
2017-08-17 |
Acerta Pharma B.V. |
BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
|
|
TW201609099A
(zh)
*
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
|
SMT202100674T1
(it)
|
2014-08-11 |
2022-01-10 |
Acerta Pharma Bv |
Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
|
|
RS63364B1
(sr)
|
2014-08-11 |
2022-07-29 |
Acerta Pharma Bv |
Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
|
|
WO2016024232A1
(en)
*
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
|
|
WO2016027781A1
(ja)
|
2014-08-18 |
2016-02-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
単環ピリジン誘導体の塩およびその結晶
|
|
EP3191098A4
(en)
*
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016055982A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
WO2016106626A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
|
|
WO2016106625A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
WO2016106624A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Tertiary alcohol imidazopyrazine btk inhibitors
|
|
WO2016106629A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
WO2016106623A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Benzamide imidazopyrazine btk inhibitors
|
|
WO2016106627A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
WO2016128912A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
CN114984013A
(zh)
|
2015-03-25 |
2022-09-02 |
国立癌症研究中心 |
胆管癌治疗剂
|
|
WO2016161571A1
(en)
|
2015-04-08 |
2016-10-13 |
Merck Sharp & Dohme Corp. |
Indazole and azaindazole btk inhibitors
|
|
WO2016192074A1
(en)
*
|
2015-06-04 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
IL293821A
(en)
|
2015-07-02 |
2022-08-01 |
Acerta Pharma Bv |
Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
|
|
US20190008859A1
(en)
*
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
WO2017077507A1
(en)
|
2015-11-06 |
2017-05-11 |
Acerta Pharma B.V. |
Imidazopyrazine inhibitors of bruton's tyrosine kinase
|
|
AU2016374441B2
(en)
|
2015-12-17 |
2021-10-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for breast cancer
|
|
EP3402503B1
(en)
|
2016-01-13 |
2020-10-21 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
|
US10640512B2
(en)
|
2016-06-30 |
2020-05-05 |
Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. |
Imidazopyrazinamine phenyl derivative and use thereof
|
|
WO2018002958A1
(en)
|
2016-06-30 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazide containing compounds as btk inhibitors
|
|
CN109851620B
(zh)
*
|
2016-08-17 |
2020-08-07 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制酪氨酸激酶活性的稠合双环类化合物
|
|
WO2018064797A1
(zh)
*
|
2016-10-05 |
2018-04-12 |
杭州领业医药科技有限公司 |
Acp-196的晶型及其制备方法和药物组合物
|
|
CN107056786B
(zh)
*
|
2016-10-14 |
2019-05-07 |
苏州明锐医药科技有限公司 |
阿卡替尼的制备方法
|
|
CN108101905A
(zh)
*
|
2016-11-24 |
2018-06-01 |
中国科学院上海药物研究所 |
嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
|
|
ES2856248T3
(es)
*
|
2016-12-21 |
2021-09-27 |
Acerta Pharma Bv |
Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
|
|
WO2018115965A1
(en)
|
2016-12-23 |
2018-06-28 |
Acerta Pharma Bv |
Solid forms of imidazopyrazine compounds
|
|
CN106588937B
(zh)
*
|
2017-01-16 |
2018-09-21 |
东莞市真兴贝特医药技术有限公司 |
咪唑并吡嗪类化合物及其制备方法和应用
|
|
US20190376971A1
(en)
|
2017-01-19 |
2019-12-12 |
Acerta Pharma B.V. |
Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
|
|
CN106831787B
(zh)
|
2017-01-20 |
2018-10-23 |
成都倍特药业有限公司 |
用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
|
|
US10899770B2
(en)
|
2017-02-20 |
2021-01-26 |
Hangzhou Solipharma Co., Ltd. |
Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
|
|
US10314844B2
(en)
|
2017-02-24 |
2019-06-11 |
Gilead Sciences, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
US10370381B2
(en)
|
2017-02-24 |
2019-08-06 |
Gilead Sciences, Inc. |
Inhibitors of bruton'S tyrosine kinase
|
|
US11554118B2
(en)
*
|
2017-03-22 |
2023-01-17 |
Xibin Liao |
Bruton's tyrosine kinase inhibitors
|
|
RS65386B1
(sr)
|
2017-04-14 |
2024-04-30 |
Biogen Ma Inc |
Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
|
|
US10800787B2
(en)
|
2017-04-20 |
2020-10-13 |
Apotex Inc. |
Process for the preparation of acalabrutinib
|
|
WO2018229613A1
(en)
*
|
2017-06-13 |
2018-12-20 |
Dr. Reddy's Laboratories Limited |
Solid forms of acalabrutinib and process for preparation thereof
|
|
CN107522701B
(zh)
*
|
2017-09-01 |
2019-11-08 |
苏州富士莱医药股份有限公司 |
一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
|
|
CN107602564B
(zh)
*
|
2017-09-20 |
2019-08-30 |
南京亘泰医药技术有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
AU2018335617B2
(en)
|
2017-09-25 |
2021-12-09 |
Astrazeneca Ab |
Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
|
|
CN109836416B
(zh)
*
|
2017-11-27 |
2023-02-03 |
苏州鹏旭医药科技有限公司 |
一种化合物的制备方法
|
|
US11161851B2
(en)
|
2017-11-06 |
2021-11-02 |
Suzhou Pengxu Pharmatech Co. Ltd. |
Processes to produce acalabrutinib
|
|
KR20200106511A
(ko)
*
|
2018-01-05 |
2020-09-14 |
크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. |
아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
|
|
CN108250186B
(zh)
*
|
2018-02-07 |
2020-01-14 |
杭州科巢生物科技有限公司 |
Acalabrutinib及其中间体的合成方法
|
|
CN110256438B
(zh)
*
|
2018-03-12 |
2020-07-17 |
新发药业有限公司 |
一种阿可替尼的制备方法
|
|
BR112020017922A2
(pt)
|
2018-03-28 |
2020-12-22 |
Eisai R&D Management Co., Ltd. |
Agente terapêutico para carcinoma hepatocelular
|
|
US20210113568A1
(en)
|
2018-04-27 |
2021-04-22 |
Ono Pharmaceutical Co., Ltd. |
PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
|
|
TW202014184A
(zh)
|
2018-04-30 |
2020-04-16 |
瑞典商阿斯特捷利康公司 |
用於治療癌症之組合
|
|
WO2019239374A1
(en)
|
2018-06-13 |
2019-12-19 |
Acerta Pharma B.V. |
Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
|
|
EA202190056A1
(ru)
|
2018-06-19 |
2021-05-28 |
Ридженерон Фармасьютикалз, Инк. |
АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
|
|
EP3587421A1
(en)
|
2018-06-29 |
2020-01-01 |
Sandoz AG |
Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
|
|
KR20250119664A
(ko)
*
|
2018-08-29 |
2025-08-07 |
아세르타 파마. 비.브이. |
4-｛8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일｝N-(피리딘-2-일)-벤즈아미드의제조 공정
|
|
WO2020053795A2
(en)
|
2018-09-13 |
2020-03-19 |
Fresenius Kabi Oncology Ltd. |
Process for the preparation of acalabrutinib and its intermediates
|
|
WO2020065667A1
(en)
|
2018-09-25 |
2020-04-02 |
Cipla Limited |
Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
|
|
CN109020977B
(zh)
*
|
2018-10-26 |
2020-11-13 |
安庆奇创药业有限公司 |
一种Acalabrutinib的制备方法
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
|
CN111377928A
(zh)
*
|
2018-12-28 |
2020-07-07 |
南京艾德凯腾生物医药有限责任公司 |
一种制备Acalabrutinib的方法
|
|
CN111377929A
(zh)
*
|
2018-12-28 |
2020-07-07 |
南京艾德凯腾生物医药有限责任公司 |
一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法
|
|
CA3126940A1
(en)
|
2019-01-18 |
2020-07-23 |
Xibin Liao |
Bruton's tyrosine kinase inhibitors
|
|
US20220194945A1
(en)
*
|
2019-02-27 |
2022-06-23 |
Optikira, LLC |
Imidazolopyridine Compounds For IRE1 Inhibition
|
|
CA3129665A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP3947386A1
(en)
|
2019-03-27 |
2022-02-09 |
Assia Chemical Industries Ltd |
Solid state forms of acalabrutinib
|
|
WO2020225831A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Msn Laboratories Private Limited, R&D Center |
Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
|
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
|
CN110563733A
(zh)
*
|
2019-09-12 |
2019-12-13 |
安帝康（无锡）生物科技有限公司 |
作为选择性btk抑制剂的咪唑并吡嗪类化合物
|
|
AU2020365951B2
(en)
|
2019-10-14 |
2026-07-16 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
DK4054582T3
(da)
|
2019-11-04 |
2025-12-01 |
Astrazeneca Ab |
Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021111465A1
(en)
|
2019-12-02 |
2021-06-10 |
Natco Pharma Limited |
Novel process for the preparation of acalabrutinib and its intermediates
|
|
KR102993352B1
(ko)
|
2019-12-20 |
2026-07-22 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
|
|
WO2021150723A1
(en)
|
2020-01-22 |
2021-07-29 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN115667266A
(zh)
*
|
2020-06-01 |
2023-01-31 |
豪夫迈·罗氏有限公司 |
新型咪唑并吡嗪衍生物
|
|
CR20230018A
(es)
|
2020-06-19 |
2023-04-11 |
Acerta Pharma Bv |
Formas farmacéuticas de maleato de acalabrutinib
|
|
CN112386597B
(zh)
*
|
2020-10-15 |
2022-03-15 |
天津济坤医药科技有限公司 |
泽布替尼在制备治疗肺纤维化疾病药物中的应用
|
|
CN113264938B
(zh)
*
|
2021-07-21 |
2021-11-02 |
北京鑫开元医药科技有限公司 |
一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用
|
|
WO2023014817A1
(en)
|
2021-08-03 |
2023-02-09 |
Syros Pharmaceuticals, Inc. |
Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
|
|
WO2025125383A1
(en)
|
2023-12-11 |
2025-06-19 |
Synthon B.V. |
Crystalline forms of acalabrutinib hydrogen maleate
|
|
US12414950B1
(en)
|
2024-05-21 |
2025-09-16 |
Telios Pharma Inc. |
Methods of treating indolent systemic mastocytosis
|
|
WO2026117542A1
(en)
|
2024-11-26 |
2026-06-04 |
Arvinas Operations, Inc. |
Combination therapy for the targeted degradation of bcl6
|